Safety Study of an Oral Vitamin D Analog in Postmenopausal Women

NCT01969656 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-07-27

No results posted yet for this study

Summary

Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.

Conditions

  • Postmenopausal Osteoporosis, Multiple Sites

Interventions

DRUG

2MD

DRUG

Calcitriol

DRUG

Placebo

Sponsors & Collaborators

  • Deltanoid Pharmaceuticals

    lead INDUSTRY

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2004-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01969656 on ClinicalTrials.gov